Key result
E4BP4 overexpression attenuates angiotensin II-induced cardiomyocyte hypertrophy and apoptosis via direct TRAIL promoter inhibition.
Why the study?
E4-binding protein 4 (E4BP4) is implicated in cardiac stress and reportedly suppresses TRAIL, a cytokine affecting cardiovascular diseases, but their role and underlying mechanism in pathological cardiac hypertrophy remained unclear.
Does E4BP4 overexpression attenuate pathological cardiac hypertrophy and cardiomyocyte apoptosis by regulating TRAIL and its receptors in mouse models of cardiac hypertrophy?
Does E4BP4 overexpression attenuate pathological cardiac hypertrophy and cardiomyocyte apoptosis by regulating TRAIL and its receptors in mouse models of cardiac hypertrophy?
This preclinical study identifies E4BP4 as a transcriptional repressor of TRAIL that mitigates cardiomyocyte hypertrophy and apoptosis, suggesting the E4BP4/TRAIL axis as a potential molecular target for pathological cardiac hypertrophy and heart failure.
Answers are grounded in this paper and cite their sources.
E4BP4-TRAIL modulation may mitigate hypertrophy in mice; leaves open human therapeutic translation.
Pathological cardiac hypertrophy (PCH) leads to heart failure. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a multifunctional cytokine, affects cardiovascular diseases. E4-binding protein 4 (E4BP4), implicated in cardiac stress, reportedly suppresses TRAIL. However, their role in PCH remains unclear. This study aims to investigate the role of E4BP4 in PCH and its underlying mechanism. Transverse aortic constriction (TAC) was used to induce PCH in mice. Echocardiography assessed cardiac function at 4, 6, 8, and 12 weeks post-surgery. Masson staining, immunofluorescence, qRT-PCR, and western blot were used to evaluate myocardial hypertrophy, fibrosis, and expression of E4BP4, TRAIL, and related receptors. Angiotensin II (Ang II)-induced hypertrophy was established in primary mouse cardiomyocytes. Cells were transfected with E4BP4 silencing or overexpression vectors. qRT-PCR, western blot, ELISA, phalloidin staining, and luciferase reporter assays measured E4BP4, TRAIL, receptors, hypertrophy/apoptosis markers, cell size, and E4BP4-TRAIL promoter binding. In hypertrophic mice, left ventricular ejection fraction and fractional shortening decreased, while left ventricular end-systolic diameter and mass increased, accompanied by aggravated myocardial fibrosis and abnormal hypertrophy markers. Ang II-induced cardiomyocytes showed increased cell area and abnormal expression of E4BP4, TRAIL, hypertrophy markers, and apoptosis-related proteins. Silencing E4BP4 exacerbated these changes, whereas overexpression reversed them. Luciferase assay confirmed that E4BP4 directly inhibited TRAIL promoter activity. In conclusion, E4BP4 mitigates hypertrophy and apoptosis by inhibiting TRAIL promoter activity and regulating TRAIL and its receptors, offering a potential therapeutic target for PCH.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied Pathological cardiac hypertrophy (n=12). Transverse aortic constriction (in vivo) and E4BP4 overexpression or silencing in Angiotensin II-treated cardiomyocytes (in vitro) vs. Sham surgery (in vivo) and negative control vectors OE-NC / si-NC (in vitro) was evaluated on Left ventricular ejection fraction (EF %) at 12 weeks in vivo (p=<0.01). E4BP4 overexpression attenuated angiotensin II-induced cardiomyocyte hypertrophy and apoptosis by directly inhibiting TRAIL promoter activity, whereas TAC reduced LVEF to in sham mice at 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: